利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

826 条记录 (耗时 0.035 秒)

    MOLECULAR BARCODING FOR MULTIPLEX SEQUENCING
    71.
    发明公开
    MOLECULAR BARCODING FOR MULTIPLEX SEQUENCING 审中-公开
    MOLEKULARE STRICHCODIERUNGFÜRMULTIPLEX-SEQUENZIERUNG

    公开(公告)号：EP3004367A2

    公开(公告)日：2016-04-13

    申请号：EP14808275.3

    申请日：2014-06-06

    申请人： Athena Diagnostics Inc.

    发明人： ELZINGA, Christopher, D.

    IPC分类号： C12P19/34 ,  C40B40/06 ,  C07H21/02 ,  C07H21/04

    CPC分类号： C12Q1/6883 ,  C12Q1/6869 ,  C12Q2600/158 ,  C12Q2600/16 ,  C12Q2525/161 ,  C12Q2525/191 ,  C12Q2525/204

    摘要： Described herein are methods, compositions and kits for preparing samples for multiplex next generation nucleic acid sequencing. The methods entail the use of in-line barcodes that minimize barcode-confusing chimeras, purification procedures with low cost, and/or a quantitative amplification to generate a desired amount of polynucleotides for sequencing.

    摘要翻译： 本文描述了用于制备用于多重下一代核酸测序的样品的方法，组合物和试剂盒。 所述方法需要使用最小化条形码混淆嵌合体的直列条形码，低成本的纯化程序和/或定量扩增以产生所需量的用于测序的多核苷酸。

    IDENTIFYING AFFINITY-MATURED HUMAN ANTIBODIES
    77.
    发明公开
    IDENTIFYING AFFINITY-MATURED HUMAN ANTIBODIES 审中-公开
    鉴定亲和力成熟的人抗体

    公开(公告)号：EP2731965A4

    公开(公告)日：2015-06-03

    申请号：EP12811637

    申请日：2012-07-12

    申请人： XBIOTECH INC

    发明人： SIMARD JOHN

    IPC分类号： C07K16/00 ,  C07K16/18 ,  C12N15/11 ,  C12Q1/68 ,  C40B40/06

    CPC分类号： C07K16/005 ,  C07K16/24 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C12N15/1037 ,  C12N15/1096

    摘要： Antigen-specific immunoglobulin V-regions are identified from a library of nucleic acids amplified using polymerase chain reaction using leader sequence-specific forward primers. The use of leader sequence primers allows all V-region sequences to be amplified (including those with extensive 5' end mutations) without loss of the original 5' V gene segment sequence. These libraries can be screened for antigen-specific V-regions using eukaryotic cells engineered to express the amplified V-region-encoding nucleic acids or using bacterial phage display techniques. In the latter, a second V-region library is made using a larger than conventional set of 5' V-region primers.; The sequence errors introduced into the amplification products by this method are corrected using sequence information obtained in the products amplified by the V-region primers to screen the library created using the leader sequence primers. Amino acid sequence information from fragments of donor immunoglobulins can be used to assist in the identification of nucleic acids encoding the heavy and light chains of donor antibodies as well as to design primers to amplify such nucleic acids.

    METHOD AND APPARATUS FOR DETERMINING A PROBABILITY OF COLORECTAL CANCER IN A SUBJECT
    79.
    发明授权
    METHOD AND APPARATUS FOR DETERMINING A PROBABILITY OF COLORECTAL CANCER IN A SUBJECT 有权
    方法和设备，用于确定结肠直肠癌的概率在病人

    公开(公告)号：EP2281059B1

    公开(公告)日：2015-01-14

    申请号：EP09730647.6

    申请日：2009-04-10

    申请人： Genenews Corporation

    发明人： LIEW, Choong-Chin ,  CHAO, Samuel

    IPC分类号： C12Q1/68 ,  C40B30/02 ,  C40B30/04 ,  G06F19/00 ,  C07H21/00 ,  C40B40/06

    CPC分类号： C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  C12Q2600/16 ,  C12Q2600/166 ,  G01N33/57419 ,  G01N2800/50 ,  G01N2800/56 ,  G06F19/12 ,  G06F19/20 ,  G06F19/24

    摘要： A method of determining a probability that a human test subject has colorectal cancer as opposed to not having colorectal cancer is disclosed. The method comprises, for each gene of a set of one or more genes selected from the group consisting of ANXA3, CLEC4D, IL2RB, LMNB1, PRRG4, TNFAIP6 and VNN1: determining a level of RNA encoded by the gene in blood of the test subject, thereby generating test data; providing positive control data representing levels of RNA encoded by the gene in blood of human control subjects having colorectal cancer, and providing negative control data representing levels of RNA encoded by the gene in blood of human control subjects not having colorectal cancer; and determining a probability that the test data corresponds to the positive control data and not to the negative control data, where the probability that the test data corresponds to the positive control data and not to the negative control data represents the probability that the test subject has colorectal cancer as opposed to not having colorectal cancer.